Thomas M. Roberts

Active 1975–2024

131
Papers
33,994
Citations
98
h-index
131
i10-index

Citations

Citations per year for Thomas M. Roberts1976: 2 citations1978: 10 citations1979: 13 citations1980: 21 citations1981: 32 citations1982: 39 citations1983: 29 citations1984: 19 citations1985: 19 citations1986: 48 citations1987: 50 citations1988: 97 citations1989: 180 citations1990: 247 citations1991: 308 citations1992: 355 citations1993: 416 citations1994: 502 citations1995: 335 citations1996: 224 citations1997: 228 citations1998: 207 citations1999: 174 citations2000: 222 citations2001: 235 citations2002: 172 citations2003: 157 citations2004: 161 citations2005: 174 citations2006: 182 citations2007: 199 citations2008: 256 citations2009: 274 citations2010: 297 citations2011: 335 citations2012: 342 citations2013: 353 citations2014: 376 citations2015: 307 citations2016: 247 citations2017: 320 citations2018: 276 citations2019: 852 citations2020: 943 citations2021: 780 citations2022: 666 citations2023: 504 citations2024: 742 citations2025: 372 citations2026: 8 citations1977: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 6,315 citing papers, 39.3% of this breakdownChina: 1,665 citing papers, 10.4% of this breakdownUnited Kingdom: 1,052 citing papers, 6.5% of this breakdownGermany: 724 citing papers, 4.5% of this breakdownCanada: 608 citing papers, 3.8% of this breakdownFrance: 528 citing papers, 3.3% of this breakdownItaly: 507 citing papers, 3.2% of this breakdownJapan: 497 citing papers, 3.1% of this breakdownAustralia: 350 citing papers, 2.2% of this breakdownSwitzerland: 335 citing papers, 2.1% of this breakdownSpain: 323 citing papers, 2% of this breakdownNetherlands: 280 citing papers, 1.7% of this breakdown
0%39.3%Other 17.9%

Fields

  • Biochemistry, Genetics and Molecular Biology57.4%
  • Medicine31.1%
  • Immunology and Microbiology5%
  • Neuroscience2.6%
  • Agricultural and Biological Sciences0.9%
  • Chemistry0.9%
  • Other2.1%

Topics

  • PI3K/AKT/mTOR signaling in cancer4.5%
  • Protein Kinase Regulation and GTPase Signaling3.7%
  • Melanoma and MAPK Pathways2.7%
  • Epigenetics and DNA Methylation2.5%
  • Cancer-related Molecular Pathways2.3%
  • Ubiquitin and proteasome pathways1.8%
  • Other82.5%

Coauthors

All papers

Open in search
  1. CDK4/6 inhibition triggers anti-tumour immunity

    Authors: , , , , , , , , , , , , , , , , , , , - Nature 2017 cited by 1,563

  2. Targeting the phosphoinositide 3-kinase pathway in cancer

    Authors: , , , - Nature Reviews Drug Discovery 2009 cited by 2,750

  3. STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer

    Authors: , , , , , , , , , , , , , , , , , , - Nature Communications 2022 cited by 247

  4. PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer

    Authors: , , , , , , , , , , , , , , , , , - Cell Reports 2018 cited by 571

  5. KRAS and YAP1 Converge to Regulate EMT and Tumor Survival

    Authors: , , , , , , , , , , , , , , - Cell 2014 cited by 763

  6. PI3Kβ controls immune evasion in PTEN-deficient breast tumours

    Authors: , , , , , , , , , , , , , , , , , , , , , - Nature 2023 cited by 134

  7. TMTpro-18plex: The Expanded and Complete Set of TMTpro Reagents for Sample Multiplexing

    Authors: , , , , , , , , - Journal of Proteome Research 2021 cited by 297

  8. Spermidine‐Functionalized Injectable Hydrogel Reduces Inflammation and Enhances Healing of Acute and Diabetic Wounds In Situ

    Authors: , , , , , , , , , , , , , , , - Advanced Science 2024 cited by 68

  9. STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer

    Authors: , , , , , , , , , , , , , , , , , , - Journal for ImmunoTherapy of Cancer 2023 cited by 92

  10. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , William R. Sellers, Robert Schlegel, Jennifer A. Wargo, William C. Hahn, Levi A. Garraway - Nature 2010 cited by 1,465

  11. The metabolic function of cyclin D3–CDK6 kinase in cancer cell survival

    Authors: , , , , , , , , , , , , , , , , , , - Nature 2017 cited by 354

  12. Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Lakshmi Nayak, James R. Heath, Laura L. Horky, Tracy T. Batchelor, Rameen Beroukhim, Susan M. Chang, Azra H. Ligon, Ian F. Dunn, Dimpy Koul, Geoffrey S. Young, Michael D. Prados, David A. Reardon, W.K. Alfred Yung, Keith L. Ligon - Journal of Clinical Oncology 2019 cited by 155

  13. The X-Linked Mental Retardation Gene SMCX/JARID1C Defines a Family of Histone H3 Lysine 4 Demethylases

    Authors: , , , , , , , , , - Cell 2007 cited by 707

  14. A histone H3 lysine 27 demethylase regulates animal posterior development

    Authors: , , , , , , , , , , , , - Nature 2007 cited by 799

  15. Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Furong Yu, Gerald R. Crabtree, Amanda G. Kautzman, Stacey Gabriel, Gad Getz, Natalie Jäger, David Jones, Peter Lichter, Stefan M. Pfister, Thomas M. Roberts, Matthew Meyerson, Scott L. Pomeroy, Yoon‐Jae Cho - Nature 2012 cited by 771

  16. Essential roles of PI(3)K–p110β in cell growth, metabolism and tumorigenesis

    Authors: , , , , , , , , , , - Nature 2008 cited by 687

  17. An F876L Mutation in Androgen Receptor Confers Genetic and Phenotypic Resistance to MDV3100 (Enzalutamide)

    Authors: , , , , , , , , , , , , , , , - Cancer Discovery 2013 cited by 565

  18. RETRACTED: The mTORC1/S6K1 Pathway Regulates Glutamine Metabolism through the eIF4B-Dependent Control of c-Myc Translation

    Authors: , , , , , , , , - Current Biology 2014 cited by 266

  19. Delivery strategies and potential targets for siRNA in major cancer types

    Authors: , , , - Advanced Drug Delivery Reviews 2016 cited by 139

  20. Statin-mediated inhibition of RAS prenylation activates ER stress to enhance the immunogenicity of KRAS mutant cancer

    Authors: , , , , , , , , , , , , , , , , , - Journal for ImmunoTherapy of Cancer 2021 cited by 76

  21. Histone H4K20/H3K9 demethylase PHF8 regulates zebrafish brain and craniofacial development

    Authors: , , , , , , , , , , , , , , , , - Nature 2010 cited by 301

  22. Combination of KRAS gene silencing and PI3K inhibition for ovarian cancer treatment

    Authors: , , , , , - Journal of Controlled Release 2019 cited by 60

  23. Inhibition of the transcriptional kinase CDK7 overcomes therapeutic resistance in HER2-positive breast cancers

    Authors: , , , , , , , , , , , , , - Oncogene 2019 cited by 75

  24. The emerging role of PI3K/AKT-mediated epigenetic regulation in cancer

    Authors: , , - Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 2017 cited by 172